Q&A with Babu Padmanabhan, STEER Engineering - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Babu Padmanabhan, STEER Engineering
A Q&A with Babu Padmanabhan, Managing Director and Chief Knowledge Officer of STEER Engineering, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 8, pp. 71



Q&A with
Babu Padmanabhan, Managing Director and Chief Knowledge Officer of STEER Engineering

PharmTech:
How has the increasing focus on biopharmaceuticals affected your business?

Padmanabhan:
Our organization supports the bio/pharmaceutical industry by improving the effectiveness of the oral, skin, and intramuscular drug-delivery systems. We build the tools for engineering sustained and controlled release of drugs, enhanced bioavailability, drug-eluting stents, and implant-based, innovative drug-release systems. These methods are recent developments and have potential in both small-molecule drugs and biopharmaceuticals.

PharmTech:
How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Padmanabhan:
Because we build tools for developing and manufacturing drug products, our equipment is built with full range of instrumentation and analytical systems that are compliant with current global regulatory requirements. We provide support in meeting the requirements of the design-, installation-, operational-, and performance-qualification protocols of various companies. Because of our exposure to many such protocols, our support to companies move them towards a better set of requirements (i.e., exceeding current requirements and preparing for the future).

PharmTech:
Do you see a new industry trend emerging?

Padmanabhan:
Continuous manufacturing is gaining significant attention among the pharmaceutical industry. Life-cycle management of existing drugs has been one of the current areas of focus. There is growing interest in equipment that supports the manufacturing of potent compounds with containment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here